Senior Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Dr. Rodger’s research program is focused on Venous Thrombosis and Thrombophilia
with specific focus on 1) Thrombosis/
Thrombophilia in Pregnancy and 2) Venous Thrombosis: Optimal Management.
Venous thromboembolism (VTE) is the leading cause of maternal
mortality in Canada. Placental thrombosis may lead to the development of
placenta mediated pregnancy complications (pregnancy loss, pre-eclampsia,
placental abruption and intra-uterine growth restriction), which collectively
are leading causes of maternal and fetal/neonatal morbidity and mortality. Dr.
Rodger is currently leading/recently completed a series of studies to further
define the association between thrombophilia and the placenta mediated
pregnancy complications and examine whether thromboprohylaxis in high risk
pregnancies reduces VTE and placenta mediated pregnancy complications. His
large cohort studies and meta-analyses suggest that thrombophilias are
associated with pregnancy loss but not with pre-eclampsia or IUGR but maybe
associated with the severe forms of these complications. He also completed an
RCT that showed that low molecular weight heparin (LMWH) does not reduce
placenta mediated pregnancy complications in thrombophilic women at high risk
for placenta mediated pregnancy complications. This RCT is being complimented
by an individual patient meta-analysis of the prophylactic LMWH to prevent
pregnancy complications studies that should define which patients most benefit
and which outcomes are prevented.
VTE is a common, potentially fatal yet treatable condition and
the third leading cause of cardiovascular mortality. The acute and short term
therapy of VTE involves anticoagulants; this therapy reduces recurrent VTE and
death from recurrent VTE while on therapy but is complicated by side effects of
major bleeding and death from major bleeding. The optimal duration of
anticoagulation in patients with unprovoked VTE is on one of the most important
unanswered clinical questions. In a multi-national prospective cohort study
exploring risk factors for recurrent venous thrombosis, Dr. Rodger developed a
promising clinical decision rule, “Men continue and HERDOO2” that segregates
these patients into a low risk group (<6% VTE recurrence at 5 years) that
likely should discontinue anticoagulants and a high risk group (>30% VTE
recurrence at 5 years) that likely should continue anticoagulants. This rule is
being validated this decision rule in a multi-national 45 centre cohort study
of over 3000 unprovoked VTE patients (REVERSE II study). This and other work
may lead to better pathophysiologic understanding of this disease and lead to
new treatments and/or treatment approaches. Dr. Rodger is in the planning
stages of an RCT examining statins, an exciting potential therapies that is
simple, inexpensive, and safe, for secondary prevention of VTE in unprovoked
Dr. Marc Rodger, M.D., FRCP(C), MSc. is a Professor in the
Faculty of Medicine, Departments of Medicine, Epidemiology and Community
Medicine and Obstetrics and Gynecology. He is the Chief and Chair of the
Division of Hematology and the Head of the Thrombosis Program. He is a Senior
Scientist at the Ottawa Hospital Research Institute. He holds a Faculty of
Medicine Clinical Research Chair in Venous Thrombosis and Thrombophilia and a
Career Scientist Award from the Heart and Stroke Foundation of Canada.
Dr. Rodger received his B.Sc from McGill University and his M.D., M.Sc.
(Clinical Epidemiology) from the University of Ottawa. He completed his
residency in Internal Medicine and fellowships in Hematology and Thrombosis at
the University of Ottawa.
1. Rodger MA, Walker MC, Smith GN et al.
Is thrombophilia associated with placenta-mediated pregnancy complications? A
prospective cohort study. J Thromb Haemost 2014;12:469-478.
Rodger MA, Betancourt MT, Clark P et
al. The association of factor V leiden and prothrombin gene mutation and
placenta-mediated pregnancy complications: a systematic review and
meta-analysis of prospective cohort studies. PLoS Med 2010;7:e1000292.
Rodger MA, Hague WM, Kingdom J et al.:
Antepartum dalteparin versus no antepartum dalteparin for the prevention of
pregnancy complications in pregnant women with thrombophilia (TIPPS): a
multinational open-label randomised trial. The Lancet In press.
Rodger MA, Carrier M, Le Gal G. et al.
Meta-analysis of low-molecular-weight heparin to prevent recurrent
placenta-mediated pregnancy complications. Blood 2014;123:822-828.
Rodger MA, Kahn SR, Wells PS et al.
Identifying unprovoked thromboembolism patients at low risk for recurrence who
can discontinue anticoagulant therapy. CMAJ 2008;179:417-426.